Treating Patients with SCLC with Driver Mutations

Opinion
Video

The Oncology Brothers and Eric Singhi, MD, provide clinical insights on the treatment of patients with small cell lung cancer with driver mutations.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
Related Content
Young patients with small-cell lung cancer had less favorable progression-free survival with chemoimmunotherapy.

Chemoimmunotherapy Less Safe, Efficacious in Younger ES-SCLC Population

Tim Cortese
August 19th 2025
Article
Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
August 19th 2025
Podcast
Symptom specificity is now included in updated guidelines for SCLC relating to LEMS, characterized by proximal muscle weakness and autonomic dysfunction.

NCCN Guidelines Add LEMS Antibody Testing for SCLC

Roman Fabbricatore
August 19th 2025
Article
Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Considering Dosing and AE Management Strategies With Tarlatamab in SCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
August 19th 2025
Podcast
Explore innovative strategies and emerging therapies transforming small cell lung cancer treatment, enhancing patient outcomes and survival rates.

3 Things You Should Know About Evolving Strategies in SCLC: Limited-Stage Advances, Frontline Innovation, and Postplatinum Progress

ONCOLOGY Staff
August 19th 2025
Article
The investigational agent showed particularly strong efficacy in an ES-SCLC subgroup with a chemotherapy-free interval of 90 or more days.

Real-World Lurbinectedin Exhibits Safety and Modest Efficacy in ES-SCLC

Roman Fabbricatore
August 19th 2025
Article